Ria Schönauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ria Schönauer has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Jan Halbritter
Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany
2 shared publications - Albertien M. van Eerde
Department of Genetics, University Medical Center Utrecht, Utrecht, Netherlands
1 shared publication - Amr Al-Shebel
Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany
1 shared publication - Annika Fendler
Charité -Universitätsmedizin
1 shared publication - Bernhard Ralla
Department of Urology, Charité – University Hospital Berlin, Berlin, Germany
1 shared publication Bert van der Zwaag
Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
Base Editing as a Therapeutic Strategy for Autosomal Dominant Tubulointerstitial Kidney Disease caused by Pathogenic UMOD Variants
Autosomal dominant tubulointerstitial kidney disease caused by pathogenic UMOD variants (ADTKD- UMOD ) is an untreatable monogenic kidney disease in which misfolded uromodulin is retained in the endoplasmic reticulum and exerts a toxic gain-of-function effect. Here we systematically evaluate the full spectrum of base editing strategies targeting the UMOD locus. Base editors corrected a representative missense patient variant, p.Cys170Tyr, with A-to-G conversion efficiencies of up to 83.4%, restoring uromodulin trafficking to the plasma membrane in cell lines and in human 3D kidney tubuloids. Mutation-agnostic inactivation was achieved by four routes: premature stop codon introduction, splice-site disruption, allele-specific stop codon introduction and promoter attenuation. Maximum on-target efficiencies ranged from 44.1% to 71.9%, providing a strategy set applicable across the UMOD allelic spectrum. Endogenous UMOD expression is rarely recapitulated in human cell models, leaving strategies that act on the endogenous gene difficult to assess in patient cells. We therefore established CRISPR activation (CRISPRa) of the endogenous UMOD promoter and confirmed its ability to upregulate UMOD expression in human urine-derived cells. This approach further enabled quantification of endogenous UMOD transcript reduction following base editing in HEK293 cells. These results establish base editing as a versatile approach for ADTKD- UMOD and provide a primary human system for testing interventions targeting endogenous UMOD expression, from nucleic acid-based silencing to small molecules.
Open AccessBase Editing as a Therapeutic Strategy for Autosomal Dominant Tubulointerstitial Kidney Disease caused by Pathogenic UMOD Variants
Autosomal dominant tubulointerstitial kidney disease caused by pathogenic UMOD variants (ADTKD- UMOD ) is an untreatable monogenic kidney disease in which misfolded uromodulin is retained in the endoplasmic reticulum and exerts a toxic gain-of-function effect. Here we systematically evaluate the full spectrum of base editing strategies targeting the UMOD locus. Base editors corrected a representative missense patient variant, p.Cys170Tyr, with A-to-G conversion efficiencies of up to 83.4%, restoring uromodulin trafficking to the plasma membrane in cell lines and in human 3D kidney tubuloids. Mutation-agnostic inactivation was achieved by four routes: premature stop codon introduction, splice-site disruption, allele-specific stop codon introduction and promoter attenuation. Maximum on-target efficiencies ranged from 44.1% to 71.9%, providing a strategy set applicable across the UMOD allelic spectrum. Endogenous UMOD expression is rarely recapitulated in human cell models, leaving strategies that act on the endogenous gene difficult to assess in patient cells. We therefore established CRISPR activation (CRISPRa) of the endogenous UMOD promoter and confirmed its ability to upregulate UMOD expression in human urine-derived cells. This approach further enabled quantification of endogenous UMOD transcript reduction following base editing in HEK293 cells. These results establish base editing as a versatile approach for ADTKD- UMOD and provide a primary human system for testing interventions targeting endogenous UMOD expression, from nucleic acid-based silencing to small molecules.
- Open Access
KidneyNetwork: Using kidney-derived gene expression data to predict and prioritize novel genes involved in kidney disease
Background: Genetic testing in patients with suspected hereditary kidney disease may not reveal the genetic cause for the disorder as potentially pathogenic variants can reside in genes that are not yet known to be involved in kidney disease. To help identify these genes, we have developed KidneyNetwork, that utilizes tissue-specific expression to predict kidney-specific gene functions. Methods: KidneyNetwork is a co-expression network built upon a combination of 878 kidney RNA-sequencing samples and a multi-tissue dataset of 31,499 samples. It uses expression patterns to predict which genes have a kidney-related function and which (disease) phenotypes might result from variants in these genes. We applied KidneyNetwork to prioritize rare variants in exome sequencing data from 13 kidney disease patients without a genetic diagnosis. Results: KidneyNetwork can accurately predict kidney-specific gene functions and (kidney disease) phenotypes for disease-associated genes. Applying it to exome sequencing data of kidney disease patients allowed us to identify a promising candidate gene for kidney and liver cysts: ALG6 . Conclusion: We present KidneyNetwork, a kidney-specific co-expression network that accurately predicts which genes have kidney-specific functions and can result in kidney disease. We show the added value of KidneyNetwork by applying it to kidney disease patients without a molecular diagnosis and consequently, we propose ALG6 as candidate gene in one of these patients. KidneyNetwork can be applied to clinically unsolved kidney disease cases, but it can also be used by researchers to gain insight into individual genes in order to better understand kidney physiology and pathophysiology. Significance statement: Genetic testing in patients with suspected hereditary kidney disease may not reveal the genetic cause for the patient’s disorder. Potentially pathogenic variants can reside in genes not yet known to be involved in kidney disease, making it difficult to interpret the relevance of these variants. This reveals a clear need for methods to predict the phenotypic consequences of genetic variation in an unbiased manner. Here we describe KidneyNetwork, a tool that utilizes tissue-specific expression to predict kidney-specific gene functions. Applying KidneyNetwork to a group of undiagnosed cases identified ALG6 as a candidate gene in cystic kidney and liver disease. In summary, KidneyNetwork can aid the interpretation of genetic variants and can therefore be of value in translational nephrogenetics and help improve the diagnostic yield in kidney disease patients.
Open AccessKidneyNetwork: Using kidney-derived gene expression data to predict and prioritize novel genes involved in kidney disease
Background: Genetic testing in patients with suspected hereditary kidney disease may not reveal the genetic cause for the disorder as potentially pathogenic variants can reside in genes that are not yet known to be involved in kidney disease. To help identify these genes, we have developed KidneyNetwork, that utilizes tissue-specific expression to predict kidney-specific gene functions. Methods: KidneyNetwork is a co-expression network built upon a combination of 878 kidney RNA-sequencing samples and a multi-tissue dataset of 31,499 samples. It uses expression patterns to predict which genes have a kidney-related function and which (disease) phenotypes might result from variants in these genes. We applied KidneyNetwork to prioritize rare variants in exome sequencing data from 13 kidney disease patients without a genetic diagnosis. Results: KidneyNetwork can accurately predict kidney-specific gene functions and (kidney disease) phenotypes for disease-associated genes. Applying it to exome sequencing data of kidney disease patients allowed us to identify a promising candidate gene for kidney and liver cysts: ALG6 . Conclusion: We present KidneyNetwork, a kidney-specific co-expression network that accurately predicts which genes have kidney-specific functions and can result in kidney disease. We show the added value of KidneyNetwork by applying it to kidney disease patients without a molecular diagnosis and consequently, we propose ALG6 as candidate gene in one of these patients. KidneyNetwork can be applied to clinically unsolved kidney disease cases, but it can also be used by researchers to gain insight into individual genes in order to better understand kidney physiology and pathophysiology. Significance statement: Genetic testing in patients with suspected hereditary kidney disease may not reveal the genetic cause for the patient’s disorder. Potentially pathogenic variants can reside in genes not yet known to be involved in kidney disease, making it difficult to interpret the relevance of these variants. This reveals a clear need for methods to predict the phenotypic consequences of genetic variation in an unbiased manner. Here we describe KidneyNetwork, a tool that utilizes tissue-specific expression to predict kidney-specific gene functions. Applying KidneyNetwork to a group of undiagnosed cases identified ALG6 as a candidate gene in cystic kidney and liver disease. In summary, KidneyNetwork can aid the interpretation of genetic variants and can therefore be of value in translational nephrogenetics and help improve the diagnostic yield in kidney disease patients.